# OnCo record tpmt-nudt15-genotyping (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/tpmt-nudt15-genotyping/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "tpmt-nudt15-genotyping" ;
  schema:name "TPMT and NUDT15 genotyping before thiopurines"@en ;
  schema:alternateName "TPMT testing"@en, "NUDT15 testing"@en, "thiopurine pharmacogenetics"@en, "mercaptopurine dosing genotype"@en ;
  schema:description "Before children and adults with acute lymphoblastic leukaemia start two years of daily mercaptopurine, two genes are checked; carriers of low-activity variants need a fraction of the standard dose or their bone marrow shuts down within weeks."@en ;
  schema:url <https://onco.cc/technologies/tpmt-nudt15-genotyping/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/> ;
  onco:status "standard-of-care" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/childhood-cancers/>, <https://onco.cc/cancers/leukaemia/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/oncology-pharmacogenomics/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/dpyd-genotyping/>, <https://onco.cc/technologies/ugt1a1-genotyping/> ;
  onco:drugs <https://onco.cc/drugs/mercaptopurine/>, <https://onco.cc/drugs/thioguanine/>, <https://onco.cc/drugs/methotrexate/> ;
  onco:terms <https://onco.cc/terms/dose-modification/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/pharmacokinetics/> .